[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"follicular-lymphoma-fl\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:follicular-lymphoma-fl":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,47,87,130,161,190,220,260,288,311,333,360,386,420,431,458,478,504],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100053791","registry-platform-hematologic-malignancies-rubin---extension-of-tumor-registry-lymphatic-neoplasms-100053791",false,"NCT06043011","Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms","Clinical Research Platform on Treatment, Quality of Life and Outcome of Patients With Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms","RUBIN","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Confirmed diagnosis of the respective NHL\n* If patient is alive: signed written informed consent\n\n  * For patients participating in the PRO survey: IC prior to or at day of start of respective line of treatment.\n  * For patients not participating in the PRO survey: IC latest eight weeks after start of respective line of treatment.\n\nExclusion Criteria:\n\n* No systemic therapy for respective lymphoid malignancy.","ALL","18 Years",{"count":20,"type":21},2950,"ESTIMATED","5 Years","OBSERVATIONAL","The purpose of the project is to set up a national, prospective, longitudinal, multicenter registry platform to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with hematological malignancies in Germany.",[26,27,28,29,30,31],"Chronic Lymphocytic Leukemia (CLL)","Diffuse Large B-cell Lymphoma (DLBCL)","Follicular Lymphoma (FL)","Mantle Cell Lymphoma (MCL)","Marginal Zone Lymphoma (MZL)","Waldenström's Macroglobulinemia (WM)",[33],"non-Hodgkin lymphoma (NHL)","RECRUITING","2026-07-10",{"date":37,"type":38},"2026-07-13","ACTUAL",{"date":40,"type":38},"2023-09-27",{"date":42,"type":21},"2033-12",{"name":44,"class":45},"iOMEDICO AG","INDUSTRY",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":66,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":86},"100449326","phase-1-a-study-of-nx-5948-in-adults-with-relapsedrefractory-b-cell-malignancies-100449326","NCT05131022","A Study of NX-5948 in Adults With Relapsed\u002FRefractory B-cell Malignancies","A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed\u002FRefractory B-cell Malignancies","Key Inclusion Criteria:\n\n* Age ≥18 years\n* Patients in Phase 1a (Dose Escalation) must have histologically confirmed R\u002FR CLL, SLL, DLBCL (subgroups include Richter-transformed DLBCL, germinal center B-cell type, activated B-cell type, high-grade B-cell lymphoma with MYC and BCL-2 and\u002For BCL-6 rearrangements, high-grade B-cell lymphomas NOS), FL, MCL, MZL (subtypes include EMZL, MALT, NMZL, SMZL), WM, or PCNSL.\n* Patients in Phase 1a must meet the following:\n\n  o For non-PCNSL indications, received at least 2 prior lines of therapy and have no other available therapies known to provide clinical benefit. For PCNSL, received at least 1 prior line of therapy\n* Patients in Phase 1b (Safety and Cohort Expansion) must have 1 of the following histologically documented B-cell malignancies, must meet criteria for systemic treatment, and must have received prior therapies and\u002For molecular features based on details described for each cohort: CLL or SLL, DLBCL, MCL, FL, MZL, WM, or PCNSL\u002FSCNSL.\n* Measurable disease per response criteria specific to the malignancy.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (0-2 for patients with PCNSL and secondary CNS involvement).\n* Adequate organ and bone marrow function\n\nKey Exclusion Criteria:\n\n* Known or suspected active prolymphocytic leukemia or Richter's transformation to Hodgkin's lymphoma prior to study enrollment\n* Prior treatment for the indication under study for anti-cancer intent that includes:\n\n  1. Radiotherapy within 2 weeks of planned start of study drug (excluding limited palliative radiation).\n  2. Prior systemic chemotherapy within 2 weeks of planned start of study drug.\n  3. Prior monoclonal antibody therapy within 4 weeks of planned start of study drug, except for patients enrolling in Cohort 16 (CLL with secondary wAIHA) where a 16-week washout period is required.\n  4. Prior small molecule therapy within 2 weeks or 5 half-lives (whichever is shorter) of planned start of study drug.\n  5. Autologous or allogeneic stem cell transplant within 100 days prior to planned start of study drug.\n  6. Chimeric antigen receptor (CAR) T-cell therapy within 100 days prior to start of study drug (within 60 days prior to start of study drug for Phase 1b).\n  7. Use of systemic corticosteroids outside of dosing limits described below and within 7 days prior to initiation of study treatment excepting those used as prophylaxis for radio diagnostic contrast. Patients with PCNSL\u002FSCNSL: no greater than 40 mg\u002Fday prednisone, or equivalent. Patients with PCNSL\u002FSCNSL using greater than 20 mg\u002Fday prednisone, or equivalent, must be clinically stable at that dose for 7 days. All other diagnoses: no greater than 20 mg\u002Fday prednisone or equivalent.\n  8. Use of systemic immunosuppressive drugs other than systemic corticosteroids for any medical condition within 60 days prior to first dose of study drug\n  9. Previously treated with a BTK degrader\n* Active, uncontrolled autoimmune hemolytic anemia (except for patients enrolling in Cohort 16) or active, uncontrolled autoimmune thrombocytopenia.\n* Patient has any of the following within 6 months of planned start of study drug:\n\n  1. Myocardial infarction, unstable angina, unstable symptomatic ischemic heart disease, or placement of a coronary arterial stent\n  2. Uncontrolled atrial fibrillation or other clinically significant arrhythmias, conduction abnormalities, or New York Heart Association (NYHA) class III or IV heart failure\n  3. Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), stroke, or intracranial hemorrhage\n  4. Any other significant cardiac condition (e.g., pericardial effusion, restrictive cardiomyopathy, severe untreated valvular stenosis, severe congenital heart disease, or persistent uncontrolled hypertension defined as systolic blood pressure \\> 160 mmHg or diastolic blood pressure \\> 100 mmHg despite optimal medical management)\n* Bleeding diathesis, or other known risk for acute blood loss.\n* History of Grade ≥ 2 hemorrhage within 28 days of planned start of study drug.\n* Active known concurrent malignancy or malignancy other than the one under study within the past 3 years. (Exceptions include, but are not limited to, patients with more recent history of basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast may enroll if they have undergone curative therapy and have no evidence of disease).",{"count":55,"type":21},572,"INTERVENTIONAL",[58],"PHASE1","This is a first-in-human Phase 1a\u002F1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.",[26,61,62,28,29,30,63,64,65],"Small Lymphocytic Lymphoma (SLL)","Diffuse Large B Cell Lymphoma (DLBCL)","Waldenstrom Macroglobulinemia (WM)","Primary Central Nervous System Lymphoma (PCNSL)","Secondary Central Nervous System Lymphoma (SCNSL)",[67,68,69,70,71,72,73,74,75,76],"BTK Degrader","BTK Inhibitor","B-Cell Malignancy","Lymphoma","C481","C481S","Bruton's Tyrosine Kinase","NX-5948","Targeted Protein Degradation","Chimeric Targeting Molecule (CTM)","2026-06-30",{"date":79,"type":38},"2026-07-02",{"date":81,"type":38},"2022-04-13",{"date":83,"type":21},"2028-01",{"name":85,"class":45},"Nurix Therapeutics, Inc.",62,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":56,"phases":96,"briefSummary":97,"conditions":98,"keywords":101,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":129},"100321141","phase-1-a-study-of-mevrometostat-for-treatment-of-relapsedrefractory-sclc-castration-resistant-prostate-cancer-and-follicular-lymphoma-100321141","NCT03460977","A Study of Mevrometostat for Treatment of Relapsed\u002FRefractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma","A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF 06821497 (MEVROMETOSTAT) IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED\u002FREFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)","Part 1 and Part 2 (Closed for enrollment).\n\nPart 3 Key Inclusion Criteria:\n\n* Histological or cytological diagnosis of castration resistant prostate cancer.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-2 with expected life expectancy of at least 6 months.\n* Adequate bone marrow, renal, and liver function\n\nPart 3 Key Exclusion Criteria:\n\n* Prior irradiation to \\>25% of the bone marrow.\n* QTcF interval \\>480 msec at screening.\n* Hypertension that cannot be controlled by medications (\\>150\u002F90 mmHg despite optimal medical therapy).\n* Known or suspected hypersensitivity to PF 06821497 or any components or enzalutamide (CRPC)\n* Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery.\n* Current use or anticipated need for food or drugs that are known strong and moderate CYP3A4\u002F5 inducers or inhibitors\n* Prior enzalutamide within the last 4 weeks\n* DDI SUBSTUDY:\n* history of CHF or evidence of ventricular dysfunction\n* fructose intolerance\n* coadministration of CYP3A4 substrates",{"count":95,"type":21},453,[58],"The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed\u002F Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL). The study consists of 3 parts; Part 1 and 2 enrolled participants with SCLC, metastatic CRPC, and FL are closed for enrollment.\n\nPart 3, which is open for enrollment is seeking men who:\n\n* have Castration Resistant Prostate Cancer (CRPC) and\n* have previously received treatment for CRPC and have progressed from the last treatment\n\nAll participants in Part 3 of this study will receive mevrometostat and\u002F or enzalutamide. Part 3 consists of 2 sub studies each has an assessment phase and a maintenance phase. The Part 3 DDI substudy consist of 2 cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (Combination cohort).\n\nIn the assessment phase:\n\n* participants in the BE substudy will take 3 single doses of mevrometostat by mouth over 3 periods.\n* participants in the DDI substudy Cohort 1 (monotherapy cohort) will take mevrometostat 2 times a day and\u002For itraconazole 1 time a day based on a present schedule.\n* participants in the DDI substudy Cohort 2 (combination cohort) will take mevrometostat 2 times a day, enzalutamide 1 time a day, and\u002For itraconazole 1 time a day based on a present schedule.\n\nAfter completion of the assessment phase, participants will enter the maintenance phase where they will receive mevrometostat 2 times a day and enzalutamide 1 time a day by mouth until their cancer is no longer responding.\n\nThe study will look at the experiences of participanrs receiving the study medicine. This will help see if the study medicine is safe and effective.",[99,100,28],"Metastatic Castration Resistant Prostate Cancer (mCRPC)","Small Cell Lung Cancer (SCLC)",[102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119],"EZH2","enhancer of zeste homolog 2","castrate resistant prostate cancer","prostatecancer-study.com","mCRPC","efficacy","safety","pharmacokinetics","pharmacodynamics","dose escalation","dose expansion","open-label","small cell lung cancer","SCLC","follicular lymphoma","FL","relapsed","refractory","2026-06-29",{"date":122,"type":38},"2026-07-01",{"date":124,"type":38},"2018-04-17",{"date":126,"type":21},"2029-07-07",{"name":128,"class":45},"Pfizer",83,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":56,"phases":140,"briefSummary":142,"conditions":143,"keywords":146,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":160},"100556568","phase-2-surovatamig-azd0486-as-monotherapy-in-participants-with-relapsedrefractory-rr-b-cell-nhl-100556568","NCT06526793","Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed\u002FRefractory (R\u002FR) B-cell NHL","A Modular Phase 2, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Surovatamig (AZD0486) in Participants With Relapsed or Refractory (R\u002FR) B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B)","SOUNDTRACK-B","1. Key Inclusion Criteria:\n\n   * Aged 18 years old and above\n   * Histologically confirmed relapsed refractory FL (Module 1) and LBCL (Module 2) after at least 2 prior lines of therapy\n   * ECOG performance status 0 to 2\n   * Locally confirmed CD-19 expression in lymphoma cells after progression from last CD 19 directed therapy\n   * FDG-avid disease with at least one bi-dimensionally measurable nodal lesion (defined as \\> 1.5 cm in its longest dimension), or extranodal lesion (defined as \\> 1.0 cm in its longest dimension)\n   * Adequate hematological function: ANC ≥ 1000\u002Fmm3, platelets\n\n     * 75,000\u002Fmm3, hemoglobin ≥ 9 g\u002FdL. Transfusion and\u002For growth factor are allowed but counts must be stable for at least 72 hours afterwards prior to screening\n   * Adequate liver function: total bilirubin \\\u003C1.5x ULN, AST\u002FALT ≤ 3xULN or \\\u003C 5 × ULN in the presence of lymphoma involvement of the liver\n   * Adequate renal function: creatinine clearance (CrCl) of ≥ 45 mL\u002Fmin\n   * Adequate cardiac function, defined as left ventricular ejection fraction (LVEF) ≥ 45% by echocardiogram or MUGA\n\n   The above is a summary, other inclusion criteria details may apply.\n2. Key Exclusion Criteria:\n\n   * Diagnosis of CLL, Burkitt lymphoma, or Richter's transformation\n   * Active CNS involvement by B-NHL\n   * Leukemic presentation of B-NHL\n   * History of a clinically relevant CNS medical condition or pathology that required treatment in the preceding year, is currently symptomatic, or that the treating investigator considers to have the potential to interfere with the evaluation of safety, such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, neurodegenerative disorder including Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis or other severe mental illness.\n   * Prior therapy with T-cell engager (TCE) within 8 weeks, autologous Hematopoietic Stem Cell Transplantation (HSCT) within 12 weeks, CAR T- cell therapy within 6 months, or prior allogeneic HSCT within 24 weeks of first dose of surovatamig\n   * Requires chronic immunosuppressive therapy\n   * Unresolved non hematological AEs ≥ Grade 2 from prior therapies; history of ≥ Grade 3 CRS or neurotoxicity from prior CAR-T or TCE therapy\n   * History of major cardiac abnormalities.\n   * If female, participant must not be pregnant or breastfeeding.\n\nThe above is a summary, other exclusion criteria details may apply.",{"count":139,"type":21},270,[141],"PHASE2","This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of surovatamig (AZD0486) monotherapy in adult participants with relapsed\u002Frefractory B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module 2 for LBCL.",[144,28,145],"B-cell Non-Hodgkin Lymphoma","Large B-Cell Lymphoma (LBCL)",[147,148,28,145,149,150],"AZD0486","Surovatamig","Non-Hodgkin lymphoma (NHL)","Relapsed\u002FRefractory","2026-06-22",{"date":153,"type":38},"2026-06-25",{"date":155,"type":38},"2024-11-27",{"date":157,"type":21},"2032-10-21",{"name":159,"class":45},"AstraZeneca",94,{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":56,"phases":171,"briefSummary":173,"conditions":174,"keywords":175,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":189},"100523102","phase-3-a-trial-to-learn-if-odronextamab-is-safe-and-well-tolerated-and-how-well-it-works-compared-to-rituximab-combined-with-different-types-of-chemotherapy-for-adult-participants-with-previously-untreated-follicular-lymphoma-100523102","NCT06091254","A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma","A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator's Choice in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-1)","OLYMPIA-1","Key Inclusion Criteria:\n\n1. Diagnosis of Cluster of Differentiation 20\\^+ (CD20\\^+) FL Grade 1-3a, stage II bulky or stage III \u002F IV\n2. Need for treatment as described in the protocol\n3. Have measurable disease on cross-sectional imaging documented by diagnostic imaging Computed Tomography (CT) or Magnetic Resonance Imaging (MRI)\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n5. Adequate bone marrow function and hepatic function, as described in the protocol\n\nKey Exclusion Criteria:\n\n1. Central Nervous System (CNS) lymphoma or leptomeningeal lymphoma\n2. Histological evidence of transformation to a high-grade or diffuse large B-cell lymphoma\n3. Waldenström Macroglobulinemia (WM, lymphoplasmacytic lymphoma), Grade 3b follicular lymphoma, chronic lymphocytic leukemia, or small lymphocytic lymphoma\n4. Treatment with any systemic anti-lymphoma therapy\n5. Infections and allergy\u002Fhypersensitivity to study drug or excipient, as described in the protocol\n\nNOTE: Other protocol defined inclusion\u002Fexclusion criteria apply",{"count":170,"type":21},822,[172],"PHASE3","This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL).\n\nThis study will be made up of two parts: Part 1 (non-randomized) and Part 2 (randomized - controlled).\n\nThe aim of Part 1 of the study is to see how safe and tolerable the study drug is when given alone.\n\nThe aim of Part 2 of the study is to see how the study drug works compared to rituximab (called the \"comparator drug\") and chemotherapy (the current standard of care for NHL). Standard of care means the usual medication expected and used when receiving treatment for a condition.\n\nThe study is looking at several other research questions, including:\n\n* What side effects may happen from taking the study drug\n* How much study drug is in the blood at different times\n* Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)\n* How the study drug affects quality of life and ability to complete routine daily activities.",[28],[176,177,178,179,180],"Non-Hodgkin lymphomas (NHLs)","Indolent NHL","B-cells NHL (B-NHL)","Follicular lymphoma","Odronextamab",{"date":182,"type":38},"2026-06-24",{"date":184,"type":38},"2023-12-12",{"date":186,"type":21},"2029-11-03",{"name":188,"class":45},"Regeneron Pharmaceuticals",190,{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":56,"phases":199,"briefSummary":200,"conditions":201,"keywords":206,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":219},"100591414","phase-1-dose-determining-study-of-exs73565-in-participants-with-relapsed-or-refractory-b-cell-malignancies-100591414","NCT06980116","Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies","A Phase 1 Open-label, Multicenter, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of EXS73565 in Participants With Relapsed or Refractory B-cell Malignancies","Key Inclusion Criteria:\n\n* Age ≥18 years at the time of signing the informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Histologically confirmed diagnosis of one of the following B-cell malignancies: chronic lymphocytic leukemia (CLL), including Richter's transformation from CLL, mantle-cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, or waldenström macroglobulinaemia.\n* Participants that have relapsed after standard of care or have progressed during standard of care or are not suitable for standard of care therapy\n\nKey Exclusion Criteria:\n\n* Any medical or psychiatric condition that, in the view of the Principal Investigator, could jeopardize or would compromise the participant's safety or ability to participate in the study.\n* Known central nervous system (CNS) malignancy or primary CNS lymphoma.\n* Concurrent active or previous malignancy (other than the primary lymphoma\u002FCLL for which the participant will be treated on this protocol within 5 years prior to randomization; participants with prior cancers may be enrolled with documented Sponsor approval.\n* Received anticancer therapy, including chemotherapy, immunotherapy, radiation therapy (with the exception of palliative radiotherapy), biologic therapy, cancer-related hormonal therapy, or any investigational therapy within 14 days or 5 half-lives (whichever is shorter) before the first dose of the study treatment.",{"count":198,"type":21},85,[58],"The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with relapsed\u002Frefractory B-cell malignancies.",[202,203,28,30,29,204,205],"Relapsed or Refractory B-cell Malignancies","Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma (CLL\u002FSLL)","Diffuse-large B-cell Lymphoma (DLBCL)","Waldenstrom's Macroglobulinemia (WM)",[207,208,28,30,29,204,205,209],"B-cell Malignancies","Chronic lymphocytic leukemia\u002Fsmall lymphocytic lymphoma (CLL\u002FSLL)","MALT1","2026-06-09",{"date":212,"type":38},"2026-06-11",{"date":214,"type":38},"2025-03-31",{"date":216,"type":21},"2028-12",{"name":218,"class":45},"Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.",9,{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":56,"phases":230,"briefSummary":231,"conditions":232,"keywords":233,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":259},"100530819","phase-3-study-of-subcutaneous-epcoritamab-in-combination-with-intravenous-rituximab-and-oral-lenalidomide-r2-to-assess-adverse-events-and-change-in-disease-activity-in-adult-participants-with-previously-untreated-follicular-lymphoma-100530819","NCT06191744","Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma","A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)","EPCORE™FL-2","Inclusion Criteria:\n\n* Diagnosis of follicular lymphoma (FL).\n* Have CD20+, histologically confirmed classic FL (previously Grade 1 to 3a FL) at most recent representative tumor biopsy based on the local pathology report, according to the 5th edition of World Health Organization (WHO) Classification of Haematolymphoid Tumours.\n* Are willing and able to comply with procedures required in the protocol.\n* Must have stage, III, IV or II with bulky disease \\>= 7cm).\n* Must be in need of systemic treatment per investigator, as evidenced by meeting at least one of the Groupe d'Etude des Lymphomes Folliculaire (GELF) criteria.\n* Has one or more target lesions:\n\n  * A positron emission tomography (PET)\u002Fcomputerized tomography (CT) scan demonstrating PET-positive lesion(s), and\n  * \\>=1 measurable nodal lesion (long axis \\>1.5cm) or \\>=1 measurable extra-nodal lesion (long axis \\>1.0 cm) on CT scan or MRI\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n* Able to receive at least one of the standard of care chemoimmunotherapy (CIT) treatment regimens: \\[Arm B\\] at the discretion of the Investigator, and rituximab and lenalidomide (R2) \\[Arm C\\].\n* Have laboratory values meeting the criteria in the protocol.\n\nExclusion Criteria:\n\n* Had major surgery within 4 weeks prior to randomization.\n* Have active cytomegalovirus (CMV) disease.",{"count":229,"type":21},1095,[172],"Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with previously untreated FL. Adverse events and change in disease condition will be assessed.\n\nEpcoritamab is an investigational drug being developed for the treatment of FL. Study doctors put the participants in 1 of 5 groups, called treatment arms. Each group receives a different treatment. Around 1095 adult participants with previously untreated FL will be enrolled in approximately 250 sites across the world.\n\nParticipants will receive R2 (intravenous \\[IV\\] infusion of rituximab (R) and oral capsules of lenalidomide) alone or in combination with subcutaneous injections of epcoritamab. Participants may also receive investigator's choice chemoimmunotherapy (CIT): IV infusion of obinutuzumab (G) and IV injections of cyclophosphamide, IV injections of doxorubicin, IV injections of vincristine, oral tablets of prednisone (CHOP) \\[G-CHOP\\]\u002F R-CHOP or G and IV infusion of bendamustine (Benda) \\[G-Benda\\]\u002FR-Benda. The total treatment duration will be 120 weeks for all arms except A2, which is 24 weeks of treatment.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.",[28],[28,234,70,235,236,237,238,239,240,241,242,243,244,245,246,247,248,249,226],"Non-Hodgkin's lymphoma (NHL)","Cancer","Epcoritamab","Rituximab","Lenalidomide","Chemoimmunotherapy (CIT)","Obinutuzumab","Cyclophosphamide","Doxorubicin Hydrochloride","Vincristine Sulfate","Prednisone","Bendamustine (Benda)","R-CHOP","G-CHOP","R-Benda","G-Benda","2026-06-01",{"date":252,"type":38},"2026-06-02",{"date":254,"type":38},"2024-02-05",{"date":256,"type":21},"2037-11",{"name":258,"class":45},"Genmab",266,{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":56,"phases":269,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":287},"100612155","phase-1-dose-escalation-and-dose-expansion-study-of-mdx2003-in-patients-with-different-types-of-lymphoma-100612155","NCT07249905","Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma","A Phase 1\u002F2 Clinical Study Evaluating MDX2003 in Participants With Relapsed, Progressive, or Refractory B-Cell Malignancies","Inclusion Criteria:\n\n* Participant must be ≥ 18 years of age.\n* Participant has a confirmed diagnosis of large B-cell lymphoma (including DLBCL, high-grade B-cell lymphoma \\[HGBCL\\], primary mediastinal B-cell lymphoma \\[PMBCL\\], etc), FL, MCL, marginal zone lymphoma, transformation of indolent B-cell lymphoma, or lymphoplasmacytic lymphoma, including Waldenstrom macroglobulinemia.\n* Participant has relapsed or progressed on at least 2 prior lines of therapy.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.\n* All participants must have measurable disease via computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET)-CT.\n* Documented CD19 or CD20 positivity of their B-cell neoplasm based on any representative pathology report from the past 3 months.\n* Adequate hematologic, hepatic and renal function.\n* All contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n* Capable of giving signed informed consent.\n\nExclusion Criteria:\n\n* Known or suspected history of hemophagocytic lymphohistiocytosis (HLH).\n* Unresolved toxicities from previous anticancer therapy.\n* Primary central nervous system (CNS) lymphoma or known CNS involvement with lymphoma.\n* Active medical condition requiring chronic systemic steroid use (\\>10 mg\u002Fday prednisone or equivalent of \\>140 mg over the last 14 days) or immunosuppressive therapy, within 6 months prior to the first dose of MDX2003.\n* Known positivity with human immunodeficiency virus (HIV), known active hepatitis B or C, or uncontrolled chronic or ongoing infection requiring intravenous treatment.\n* Participant has a history of allogenic tissue or solid organ transplant, with the exception of corneal transplants.\n* Known hypersensitivity to allopurinol or rasburicase.\n* Participant has a seizure disorder requiring therapy at the time of screening (such as steroids or anti-epileptics).\n* Participant is not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions.",{"count":268,"type":21},180,[58,141],"This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2003 in patients with different types of lymphoma",[70,272,273,274,275,276,277,28],"Waldenström Macroglobulinemia (WM)","DLBCL - Diffuse Large B Cell Lymphoma","PMBCL","HGBCL","FL Lymphoma","Lymphoplasmacytic Lymphoma","2026-04-30",{"date":280,"type":38},"2026-05-04",{"date":282,"type":38},"2026-04-13",{"date":284,"type":21},"2030-04",{"name":286,"class":45},"ModeX Therapeutics, An OPKO Health Company",2,{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":295,"enrollmentInfo":296,"targetDuration":4,"studyType":56,"phases":298,"briefSummary":299,"conditions":300,"keywords":4,"overallStatus":301,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":46},"100636156","phase-3-a-study-to-evaluate-the-safety-and-efficacy-of-sctb35-in-combination-with-lenalidomide-in-patients-with-relapsed-or-refractory-follicular-lymphoma-100636156","NCT07562022","A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma","A Phase 3 Randomized, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide Versus Rituximab and Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma","Inclusion Criteria:\n\n* Age 18-80 years old\n* Histologically confirmed Follicular lymphoma (FL) grade 1, 2, or 3a according to WHO 2022 criteria\n* Relapsed or refractory (R\u002FR) disease to at least one prior systemic regimen that contained an anti-CD20 monoclonal antibody (mAb) in combination with chemotherapy\n* Judged by the investigator, the participant must urgently need to receive systemic treatment, based on meeting at least one GELF criterion\n* A measurable or evaluable disease at the time of enrolment\n* ECOG PS 0-2\n* Adequate organ function and bone marrow function\n* Expected survival ≥ 6 months\n\nExclusion Criteria:\n\n* Documented refractoriness to lenalidomide.\n* Have lenalidomide exposure within 12 months prior to randomization","80 Years",{"count":297,"type":21},93,[172],"The purpose of this study is to evaluate the efficacy and safety of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular lymphoma (FL).",[28],"NOT_YET_RECRUITING","2026-04-24",{"date":304,"type":38},"2026-05-01",{"date":306,"type":21},"2026-05",{"date":308,"type":21},"2029-06",{"name":310,"class":45},"Sinocelltech Ltd.",{"id":312,"slug":313,"hasResults":11,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":56,"phases":321,"briefSummary":322,"conditions":323,"keywords":4,"overallStatus":301,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":46},"100635297","phase-2-sonrotoclax-zanubrutinib-and-rituximab-in-previously-untreated-patients-with-follicular-lymphoma-100635297","NCT07550855","Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma","A Phase II, Multicenter, Single-Arm Study of Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma (FLOURISH)","FLOURISH","Inclusion Criteria:\n\n1. Willing to participate in the clinical study and signed informed consent.\n2. Age ≥18 years, no gender restrictions.\n3. Pathologically diagnosed with follicular lymphoma (Grade 1, 2, or 3a) and previously untreated.\n4. Has at least one measurable or assessable lesion.\n5. Ann-Arbor stage III or IV, or stage II with bulky disease.\n6. Meets at least one GELF criterion.\n7. Eastern Cooperative Oncology Group (ECOG) performance status score ≤2.\n8. Adequate major organ function.\n\nExclusion Criteria:\n\n1. Known active central nervous system lymphoma or leptomeningeal disease.\n2. Evidence of follicular lymphoma with transformation to diffuse large B-cell lymphoma.\n3. Prior history of other malignancies other than follicular lymphoma (except for those with disease-free survival ≥5 years and assessed by the investigator as having low risk of recurrence).\n4. History of allergy to the investigational drug, similar drugs, or excipients.\n5. Known history of human immunodeficiency virus (HIV) infection and\u002For acquired immunodeficiency syndrome (AIDS).\n6. Active systemic infection requiring intravenous antibiotic therapy or hospitalization (occurring within 4 weeks prior to screening).\n7. Confirmed progressive multifocal leukoencephalopathy (PML), positive for human T-lymphotropic virus type 1 (HTLV-1), or suspected active\u002Flatent tuberculosis.\n8. Pregnant or breastfeeding women, and women of childbearing potential who are unwilling to use contraception.\n9. Patients with significant dysfunction of vital organs.\n10. Receipt of any moderate or strong CYP3A4 inhibitors or strong CYP3A4 inducers within 14 days (or 5 half-lives, whichever is longer) prior to the first dose of sotoclax.\n11. Use of strong cytochrome P450 (CYP) 3A4 inhibitors within 7 days prior to the first dose of zanubrutinib, or requirement for continuous use of strong CYP3A inhibitors\u002Finducers.\n12. Receipt of concurrent therapy for the study disease outside of this clinical study (including the screening period).\n13. Autoimmune anemia and\u002For thrombocytopenia that does not respond adequately to corticosteroids or other standard treatments.\n14. Receipt of medications known to prolong the QT\u002FQTc interval.\n15. Vaccination with a live vaccine within ≤35 days prior to the first dose of study drug.\n16. Major surgery within 4 weeks prior to the first dose of study drug.\n17. Unwillingness or inability to complete all assessments and procedures required by the study.",{"count":320,"type":21},52,[141],"Follicular lymphoma (FL) remains an incurable indolent B-cell lymphoma for many patients, and although rituximab-based chemoimmunotherapy can achieve high initial response rates, a substantial proportion of patients experience early progression, including POD24, which is associated with poor long-term outcomes. This underscores the need for more effective and better-tolerated frontline treatment strategies, particularly chemotherapy-free approaches. The present study is based on a strong biologic rationale that simultaneously targets two key pathogenic mechanisms in FL: aberrant B-cell receptor signaling and impaired apoptosis driven by BCL2 overexpression. Zanubrutinib, a next-generation BTK inhibitor, has shown clinical activity with a favorable safety profile in FL, while sonrotoclax, a potent and highly selective next-generation BCL2 inhibitor, has demonstrated promising preclinical and early clinical activity. In combination with rituximab, this chemotherapy-free triplet regimen may produce deeper and more durable remissions while maintaining manageable toxicity, and therefore has the potential to expand frontline treatment options and improve outcomes for patients with previously untreated FL.",[28],"2026-04-19",{"date":302,"type":38},{"date":327,"type":21},"2026-09-01",{"date":329,"type":21},"2029-09-30",{"name":331,"class":332},"Sun Yat-sen University","OTHER",{"id":334,"slug":335,"hasResults":11,"nctId":336,"briefTitle":337,"officialTitle":337,"acronym":4,"eligibilityCriteria":338,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":339,"enrollmentInfo":340,"targetDuration":4,"studyType":56,"phases":342,"briefSummary":344,"conditions":345,"keywords":347,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":356,"leadSponsor":358,"locationsCount":46},"100635131","early-phase-1-a-clinical-study-exploring-the-safety-efficacy-and-metabolic-kinetics-of-ct1182-injection-in-patients-with-relapsed--refractory-non-hodgkin-lymphoma-100635131","NCT07548697","A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed \u002F Refractory Non Hodgkin Lymphoma","Inclusion Criteria:\n\n* voluntarily participate in clinical research; I fully understand and know this study and sign the informed consent form; Willing to follow and be able to complete all research procedures;\n* age 18-75 years (inclusive);\n* r\u002Fr B-NHL diagnosed by histology or cytology includes large B-cell lymphoma, Burkitt lymphoma, mantle cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (hgbl) according to the WHO classification of lymphoproliferation and tumor (5th Edition, 2022); Grade 3B follicular lymphoma (fl3b); Follicular lymphoma (FL) or marginal zone lymphoma (MZL) - transformed DLBCL; Primary mediastinal large B-cell lymphoma (pmbcl); Burkitt lymphoma (BL); Mantle cell lymphoma (MCL).\n* have received standardized systemic treatment in the past, including anti-CD20 drugs (except CD20 negative) and anthracyclines;\n* intolerance during the last treatment, or the investigator assessed the need for new treatment after the last treatment;\n* meet at least one of the following conditions:\n\n  1. According to CT measurement: the long diameter of intranodal lesions is \\>1.5 cm, or the long diameter of extranodal lesions is \\>1.0 cm, and the short diameter can be measured;\n  2. According to PET measurement: FDG uptake score reaches 4 or 5;\n* estimated survival \\>12 weeks;\n* Eastern Cooperative Oncology Group (ECoG) score 0-1;\n* participants should meet the following test results (they have not received any granulocyte colony-stimulating factor (G-CSF) \u002F granulocyte macrophage colony-stimulating factor (GM-CSF) treatment and supportive treatment of red blood cell and platelet transfusion within 7 days before laboratory examination):\n\n  1. ;\n  2. Endogenous creatinine clearance ≥ 50 ml\u002Fmin (using Cockcroft Gault formula), or creatinine ≤ 1.5 × ULN;\n  3. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN, total bilirubin ≤ 1.5 × ULN; If lymphoma invades the liver: AST and alt ≤ 5 × ULN, total bilirubin ≤ 3.0 × ULN;\n  4. The international normalized ratio (INR) and activated partial thromboplastin time (APTT) should be ≤ 1.5 × ULN.\n  5. Blood oxygen saturation in non oxygen inhalation state ≥ 92%;\n  6. Left ventricular ejection fraction (LVEF) ≥ 50% (LVEF value is near the critical value, and can be enrolled after the investigator has fully assessed the risk);\n* female participants with childbearing potential must have a pregnancy test at the time of screening and the result is negative. They are willing to use very effective and reliable methods of contraception within 1 year after receiving study treatment. It is absolutely prohibited to donate eggs within 1 year after receiving study treatment infusion during the study period; Male participants who had active sex with women with reproductive potential were willing to use very effective and reliable methods of contraception within 1 year after receiving study treatment. All male participants were absolutely forbidden to donate sperm within 1 year after receiving study treatment infusion during the study period.\n\nExclusion Criteria:\n\n* pregnant or lactating women;\n* research participants with a history of neurological diseases, such as epilepsy, intracranial hemorrhage, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, memory impairment, spinal cord compression, mental disease or any disease involving the central nervous system, or suspected central nervous system (CNS) metastasis;\n* HIV, syphilis infection, active hepatitis B virus infection (HBV-DNA higher than the detection limit or positive), or active hepatitis C virus infection (HCV-RNA positive);\n* according to the investigator's judgment, there is currently any uncontrollable active infection, including but not limited to active tuberculosis;\n* there is known or suspected long-term active infection of EBV and a known history of HLH;\n* have received autologous stem cell transplantation or autologous cell therapy within 3 months before signing the informed consent; Previously received allogeneic stem cell transplantation or allogeneic donor derived cell adoptive therapy;\n* have received previous treatment targeting CD19 (unless the CD19 or CD20 target test is still positive);\n* previously received pseudotyped viral vector related treatment with vesicular stomatitis virus glycoprotein (VSVG) as envelope protein (including but not limited to VSVG pseudotyped lentivirus, adenovirus or other viral vector mediated gene therapy, oncolytic virus therapy, etc.);\n* CT1182 has received anti-tumor treatment within 14 days before infusion or within 5 half lives (whichever is shorter), including but not limited to cytotoxic drugs, targeted therapy, radiotherapy, epigenetic therapy or experimental drug treatment, or has used invasive experimental medical devices. ;\n* receive systemic glucocorticoids equivalent to \\>15 mg\u002F day prednisone within 7 days before signing the informed consent, except for topical glucocorticoids or physiological replacement therapy;\n* have been vaccinated within 4 weeks before signing the informed consent, or it is expected that live attenuated vaccine, inactivated vaccine or RNA vaccine will be vaccinated during the trial or within 12 months after ct1182 infusion;\n* known allergy to ct1182 or any formulation component, allergy or intolerance to tocilizumab, or previous history of other serious allergies such as anaphylactic shock;\n* study participants with any of the following cardiac diseases:\n\n  1. The New York Heart Association (NYHA) cardiac function classification was grade III or IV heart failure;\n  2. Myocardial infarction, unstable angina pectoris, or coronary artery bypass grafting or coronary stent implantation occurred within 6 months before screening;\n  3. There is a history of clinically significant uncontrolled arrhythmias, such as ventricular arrhythmias;\n  4. ;\n  5. Other heart diseases that the investigator believes may endanger the safety of study participants due to participation in this study;\n* suffering from serious lung disease, and participating in this study may endanger the safety of participants according to the judgment of the investigator;\n* the second primary malignant tumor requiring treatment or incomplete remission in the past 3 years, except the following successfully treated tumors with low malignancy such as non metastatic basal cell carcinoma or squamous cell skin carcinoma, non metastatic prostate cancer, breast cancer or cervical cancer in situ, non muscle invasive bladder cancer or thyroid cancer;\n* there is active systemic autoimmune disease, which requires long-term treatment with immunosuppressants;\n* major surgery within 2 weeks before signing the informed consent, or major surgery planned during the study or within 4 weeks after giving the study treatment (excluding cataract and other local anesthesia surgery);\n* the investigator assessed that the participants were unable or unwilling to comply with the requirements of the study protocol, or were not suitable to participate in this clinical study for other reasons.","75 Years",{"count":341,"type":21},24,[343],"EARLY_PHASE1","This study is a single arm, open label, dose exploring clinical study to evaluate the safety, efficacy, metabolic kinetics and pharmacodynamics of CT1182 cells in patients with relapsed \u002F refractory B-cell non Hodgkin lymphoma (r\u002Fr B-NHL).",[346,273,28],"B-cell Non Hodgkin Lymphoma (NHL)",[348,349,350,351,117],"CT1182","CT1182-CG11014","NHL","DLBCL","2026-04-16",{"date":354,"type":38},"2026-04-23",{"date":278,"type":21},{"date":357,"type":21},"2028-12-31",{"name":359,"class":332},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"id":361,"slug":362,"hasResults":11,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":4,"eligibilityCriteria":366,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":367,"targetDuration":4,"studyType":56,"phases":369,"briefSummary":370,"conditions":371,"keywords":372,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":385},"100426218","phase-1-a-study-of-nx-2127-in-adults-with-relapsedrefractory-b-cell-malignancies-100426218","NCT04830137","A Study of NX-2127 in Adults With Relapsed\u002FRefractory B-cell Malignancies","A Phase 1, Dose Escalation, Safety and Tolerability Study of NX-2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed\u002FRefractory B-cell Malignancies","Inclusion Criteria:\n\n* Patients must be ≥ 18 years of age\n* Patients must have measurable disease per disease-specific response criteria\n* Patients with indolent forms of NHL must meet the criteria requiring systemic treatment (i.e., iwCLL, IWG, Lugano Classification of Lymphoma response criteria, or International PCNSL Collaborative Group response criteria)\n* Patients with transformed lymphoma are eligible for the study with the exception of those detailed in Exclusion Criteria #1: Prolymphocytic leukemia, MCL with blastoid histology, MCL with pleomorphic morphology, or MCL with known TP53 mutation\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (non-PCNSL indications) or 0 - 2 (PCNSL patients)\n* Adequate organ and bone marrow function\n* Patients of child-bearing potential must use adequate contraceptive measures to avoid pregnancy for the duration of the study as defined in the protocol\n\nInclusion Criteria for Patients in Phase 1a:\n\n* Have histologically confirmed R\u002FR CLL, SLL, WM, MCL, and MZL, FL, DLBCL, or PCNSL\n* Received at least 2 prior systemic therapies (or at least 1 prior therapy for patients with WM or PCNSL) and have no other therapies known to provide clinical benefit\n* Must require systemic therapy\n\nInclusion Criteria for Patients in Phase 1b:\n\n* Must have one of the following histologically documented R\u002FR B-cell malignancies:\n\n  * CLL\u002FSLL whose disease has failed treatment with a BTKi;\n  * MCL whose disease has failed treatment with BTKi and an anti-CD20 mAb-based regimen\n  * FL or MZL whose disease has failed treatment with an anti-CD20 mAb-based regimen; or WM whose disease has failed treatment with a BTKi\n  * PCNSL whose disease failed at least 1 prior line of treatment\n  * DLBCL whose disease has failed treatment with an anti-CD20 mAb-based regimen and either: an anthracycline-based regimen; or an anti-CD19-based regimen, or another\u002F palliative regimen (either progressed post stem cell transplant or transplant-ineligible)\n\nExclusion Criteria:\n\n* Active, uncontrolled autoimmune hemolytic anemia or autoimmune thrombocytopenia\n* History of known\u002Fsuspected other autoimmune disease (exception(s): patients with alopecia, vitiligo, resolved childhood atopic dermatitis, hypothyroidism, or hyperthyroidism that is clinically euthyroid at screening are allowed.)\n* Unable to swallow capsules or have a condition that may interfere in the delivery, absorption, or metabolism of the study drug\n* Bleeding diathesis, or other known risk for acute blood loss\n* Patients requiring ongoing treatment with warfarin or an equivalent vitamin K antagonist and within 7 days prior to the first dose of study drug\n* Prior radiotherapy within 2 weeks of planned start of study drug (excluding limited palliative radiation)\n* Toxicities from previous anticancer therapies must have resolved to baseline levels or to Grade 1 (except for alopecia, hypothyroidism with adequate replacement therapy, hypopituitarism with adequate replacement therapy, peripheral neuropathy or hematologic parameters meeting inclusion criteria).\n* Active known second malignancy. Exception: patients with non-metastatic, non-melanoma skin cancer are eligible\n* Patient has had major surgery (e.g. requiring general anesthesia) within 4 weeks before the planned first dose of study drug\n* Infection with human immunodeficiency virus (HIV)-1 or HIV-2. Exception: patients with well-controlled HIV (e.g., CD4 \\> 350\u002Fmm3 and undetectable viral load) are eligible.\n* Current active liver disease from any cause\n* Active viral reactivation (e.g., CMV or EBV)\n* Use of systemic corticosteroids exceeding 20 mg\u002Fday prednisone (or equivalent) for non-PCNSL indications within 15 days prior to the planned start of study drug. PCNSL patients may not exceed corticosteroid doses of 40 mg\u002Fday prednisone (or equivalent) and should be on a stable or decreasing dose for 7 days prior to planned study start.\n* Use of non-steroidal immunosuppressive drugs within 30 days prior to start of the study\n* Clinically significant, uncontrolled cardiac, cardiovascular disease, or history of myocardial infarction within 6 months of planned start of study drug\n* Administration of any strong cytochrome P450 3A (CYP3A) inducers or inhibitors for 14 days prior to the first dose of study drug, and any P-glycoprotein inhibitors (for 2 days) or moderate inducers of CYP3A for 7 days",{"count":368,"type":21},248,[58],"This is a first-in-human Phase 1a\u002F1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.",[26,61,63,29,30,28,27,64],[67,68,373,70,374,238,375,73,376,75,76,71,72],"B-cell Malignancy","IMiD","Pomalidomide","NX-2127","2026-03-18",{"date":379,"type":38},"2026-03-20",{"date":381,"type":38},"2021-05-05",{"date":383,"type":21},"2027-05",{"name":85,"class":45},16,{"id":387,"slug":388,"hasResults":11,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":392,"eligibilityCriteria":393,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":295,"enrollmentInfo":394,"targetDuration":4,"studyType":56,"phases":396,"briefSummary":398,"conditions":399,"keywords":403,"overallStatus":301,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":415,"completionDateStruct":416,"leadSponsor":418,"locationsCount":4},"100624651","this-clinical-trial-is-a-single-arm-non-randomized-pilot-trial-to-determine-the-safety-of-administering-autologous-anti-c19-cells-ari-0001-and-the-feasibility-of-local-car-t-cell-production-in-patients-over-18-years-of-age-with-relapsedrefractory-rr-cd19-hematologic-malignancies-including-r-100624651","NCT07412405","This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed\u002FRefractory (R\u002FR) CD19+ Hematologic Malignancies, Including R","ACITAC-001: Hybrid Type Two Implementation Study of CAR-T Therapy in Colombia Based on a Pilot Clinical Trial ARI-0001 T Cells With Anti-CD19 Chimeric Antigen Receptor (CAR-T) for the Treatment of Recurrent\u002FRefractory CD19+ Hematolymphoid Neoplasms.","ACITAC-001","Inclusion Criteria:\n\n1. Participants (Men and Women) ≥ 18 and ≥ 80 years of age.\n2. Participants capable of understanding and voluntarily signing the informed consent forms (prescreening and study forms) prior to any study-related evaluation or procedure, and able to adhere to the study visit schedule and other protocol requirements.\n3. CD19+ hematologic malignancy with a histologically documented diagnosis.\n4. Inclusion criteria according to the type of CD19+ hematologic malignancy measurable by the 2014 Lugano criteria (NHL) or IWCLL criteria (CLL) or EWALL criteria (ALL).\n5. B-cell precursor acute lymphoblastic leukemia (B-ALL relapsed\u002Frefractory (R\u002FR)): Second-line or later relapse (including patients with prior blinatumumab use), second-line or later non-candidate for allogeneic transplantation, or relapse post-allogeneic transplantation.\n6. For patient inclusion, the disease must have progressed after the last regimen or the patient must not have achieved partial or complete remission with the last regimen, defined by the presence of at least 5% blasts in bone marrow or peripheral blood in an evaluation confirmed by flow cytometry or immunohistochemistry at least 2 weeks prior to recruitment (prescreening visit).\n7. The consideration of non-candidacy for allogeneic transplantation will be based on functional status, comorbidities, and persistence. Minimal Residual Disease (MRD) or lack of a donor.\n8. Relapsed\u002Frefractory diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma (R\u002FR): Refractory to first-line treatment or relapsed within the first 12 months after completion of first-line chemoimmunotherapy, including an anti-CD20 monoclonal antibody, not a candidate for autologous transplantation; or refractory after two or more lines of systemic therapy; in second (or higher) relapse post-autologous transplantation; grade 3b follicular lymphoma or transformed to relapsed or refractory large B-cell lymphoma after at least one line of standard treatment.\n9. Symptomatic relapsed\u002Frefractory follicular lymphoma (FL): In third-line therapy (after at least two treatment regimens), including anti-CD20 therapy, and with a progression-free interval of less than two years; or in Relapse after autologous or allogeneic transplantation.\n10. Relapsed\u002Frefractory (R\u002FR) mantle cell lymphoma, including Bruton's tyrosine kinase inhibitor (BTKi) therapy: In first (or higher) relapse, not a candidate for autologous or allogeneic transplantation; or in second (or higher) relapse following autologous or allogeneic transplantation.\n11. Symptomatic chronic lymphocytic leukemia (CLL): Relapse after two treatment regimens (including BTKi and BCL2 inhibitor in combination with anti-CD20) and with a progression-free interval of less than two years (POD24); or transformation to Richter syndrome, see inclusion criteria for DLBCL.\n12. Eastern Cooperative Oncology Group (ECOG) functional status ≤ 2.\n13. Life expectancy \\> 6 months, as determined by the Principal Investigator.\n14. Adequate organ function, defined as the following parameters at visit 2 Selection criteria:\n\n    1. Absolute neutrophil count (ANC) ≥ 1,000\u002Fmm3\n    2. Platelet count ≥ 50,000\u002Fmm3\n    3. Hemoglobin ≥ 10 g\u002FdL\n    4. Total bilirubin ≤ 1.5 x the institutional upper limit of normal (ULN).\n    5. AST (SGOT)\u002FALT (SGPT) ≤ 3 x the institutional ULN\n    6. Serum creatinine ≤ 2 x the institutional ULN or eGFR \\> 30 mL\u002Fmin\u002F1.73 m2\n    7. Left ventricular ejection fraction \\> 45% as determined by echocardiogram\n    8. Pulmonary function tests: FEV1 (forced expiratory volume in 1 second): ≥ 50% of predicted and FVC (forced vital capacity): ≥ 50% of predicted Predicted value and FEV1\u002FFVC ratio: ≥ 0.7 (or without significant obstruction) and SpO2 (oxygen saturation): ≥ 89% on room air at rest and hemoglobin-corrected DLCO: ≥ 70% of the predicted value.\n15. Have adequate venous access.\n16. Participants of reproductive potential must meet the following criteria:\n\n    1. Negative pregnancy test 14 days before trial enrollment and subsequently every month for the duration of the trial, or evidence of postmenopausal status or surgical sterilization.\n    2. Postmenopausal status is defined as the absence of menstruation for 12 months without an alternative medical cause. The following age-specific requirements apply:\n\n       * \\\u003C 50 years: Amenorrhea for ≥12 months after discontinuation of exogenous hormonal treatments; and luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels within the postmenopausal range as defined by the institution.\n       * ≥ 50 years: Patient with amenorrhea for 12 months or more after discontinuation of all exogenous hormonal treatments; or radiation-induced menopause with last menstrual period more than 1 year ago; or chemotherapy-induced menopause with last menstrual period more than 1 year ago.\n17. All participants of reproductive potential and those with a sexual partner of reproductive potential must agree to use a highly effective contraceptive method from the start of trial therapy until 12 months after the last infusion dose. Options for adequate contraception with a failure rate of \\\u003C1% per year include: bilateral tubal ligation\u002Focclusion; partner vasectomy; intrauterine device (IUD) or hormonal delivery system (IUS); any hormonal contraceptive (estrogen combined with progesterone or progesterone alone) combined with ovulation inhibition: implanted, oral, intravaginal, transdermal, or injectable; spermicide with a compatible barrier method (e.g., diaphragm, sponge, or condoms). Alternatively, two methods (e.g., two barrier methods, such as a condom and a cervical cap) may be combined to achieve a failure rate of \\\u003C1% per year. Barrier methods must always be supplemented with the use of spermicide. Abstinence is acceptable only if it is consistent with the patient's preferred and usual lifestyle. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulatory methods) and withdrawal are not acceptable contraceptive methods. If pregnancy is suspected or confirmed in a female patient or a female partner of a male patient during trial participation or within 12 months of ARI-0001 cell infusion, the Principal Investigator must be informed immediately.\n18. Participants with prior or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of HBsAg) are eligible.\n\n\\*Specific Inclusion Criteria Before Lymph Depletion\\*\n\nThe following criteria must be confirmed 7 days prior to lymph depletion:\n\n1. Confirmation of successful CAR-T cell fabrication.\n2. No evidence or suspicion of infection.\n3. Serum creatinine ≤ 2 times the institutional upper limit of normal (ULN) or eGFR \\>30 mL\u002Fmin\u002F1.73 m².\n4. Confirmation of compliance with washout periods.\n5. No worsening of the patient's clinical status compared to the initial eligibility criteria that, in the opinion of the treating physician, significantly increases the risk due to lymph depletion chemotherapy or excludes them from treatment with the trial CAR-T cell therapy.\n\n\\*Specific inclusion criteria prior to CAR-T cell infusion.\\*\n\nParticipants must meet the following criteria (Failure to meet these criteria will result in the individual subject's enrollment being halted or suspended entirely at the discretion of the CES and the Principal Investigator):\n\n1. No evidence or suspicion of infection.\n2. Confirmation of compliance with the washout periods.\n3. No worsening of clinical status compared to the initial eligibility criteria that, in the opinion of the treating physician, significantly increases the risk due to lymphodepleting chemotherapy or excludes them from treatment with the ARI-0001 CAR-T therapy in the trial.\n\nExclusion Criteria:\n\nThe presence of any of the following will exclude the subject from trial enrollment:\n\n1. Failure to comply with the washout periods.\n2. Autologous or allogeneic stem cell transplantation or CAR-T cell therapy within 6 weeks prior to CAR-T cell infusion.\n3. Subjects with an active infection requiring systemic treatment. This definition excludes participants with Hepatitis B (known positive hepatitis B surface antigen \\[HBsAg\\] result), latent Tuberculosis, Hepatitis C, or HIV seropositivity.\n4. History of autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus) requiring immunosuppressive medication within the past 6 months.\n5. Pregnant or breastfeeding women are excluded from this trial because CAR-T cell therapy may be associated with teratogenic or abortifacient effects. Women of childbearing potential must have a negative serum pregnancy test. Due to the unknown, but potential, risk of adverse events in infants from maternal CAR-T cell therapy, breastfeeding should be discontinued. These potential risks may also apply to other agents used in this trial.\n6. Participation in another interventional research study.\n7. Major surgery within 4 weeks prior to enrollment from which the patient has not fully recovered, as determined by the investigator.\n8. Active central nervous system (CNS) involvement due to leukemia or lymphoma, including leptomeningeal lymphoma. Patients with a history of CNS or meningeal involvement must be in documented remission, as determined by cerebrospinal fluid (CSF) evaluation, for at least 90 days prior to enrollment.\n9. Diagnosis of another malignancy within ≤ 5 years prior to trial enrollment, except for those considered adequately treated with no evidence of disease or symptoms and\u002For not requiring therapy during the trial (e.g., basal cell or squamous cell skin cancer, carcinoma in situ of the breast, bladder, or cervix, or low-grade prostate cancer with a Gleason score ≤ 6).\n10. Known brain metastases or cranial epidural disease. Note: Patients with brain metastases or cranial epidural disease adequately treated with radiotherapy and\u002For surgery and stable for at least 4 weeks prior to the first dose of trial treatment will be eligible for the trial. Subjects must be neurologically asymptomatic and not receiving corticosteroid treatment at the time of the first dose of trial treatment.\n11. Current evidence of significant uncontrolled comorbidity, including, but not limited to, the following conditions:\n\n    * New York Heart Association Class III or IV congestive heart failure, unstable angina, serious cardiac arrhythmias.\n    * Stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction (MI), or other ischemic events, or thromboembolic event (e.g., deep vein thrombosis, pulmonary embolism) within 3 months prior to the first dose.\n    * QTc prolongation defined as QTcF \\> 500 ms.\n    * Known congenital long QT syndrome.\n    * Left ventricular ejection fraction \\\u003C 45%.\n    * Uncontrolled hypertension, defined as ≥ 140\u002F90 mmHg as assessed by the average of three consecutive blood pressure measurements taken over 10 minutes.\n    * Any other condition that, in the Investigator's judgment, contraindicates the subject's participation in the clinical trial due to safety concerns or issues with compliance with clinical trial procedures (e.g., infection\u002Finflammation, bowel obstruction, inability to swallow medication \\[subjects cannot receive the medication via a feeding tube\\], social\u002Fpsychological problems, etc.).",{"count":395,"type":21},12,[397],"NA","This is a hybrid type two study, with two simultaneous development phases. Phase A involves developing a public-private partnership to create the conditions for implementing CAR-T cell therapies in Colombia. Phase B will be a single-arm, non-randomized pilot clinical trial in patients over 18 years of age with recurrent\u002Frefractory (R\u002FR) CD19+ hematopoietic lymphoid neoplasms, including R\u002FR non-Hodgkin lymphoma (NHL), R\u002FR B-cell acute lymphoblastic leukemia (B-ALL), and R\u002FR mantle cell lymphoma; and R\u002FR chronic lymphocytic leukemia (CLL) (including CLL with Richter transformation). This trial aims to determine the safety of administering autologous anti-C19 cells (ARI-0001) and the feasibility of local CAR-T cell production.\n\nPhase A of implementation aims to gather information on the domains of the multilevel model, including organizational context, suppliers, infrastructure, and institutional capacities, to identify barriers and facilitators in the implementation of CAR-T cell therapy in Colombia. National consensus will also be developed in the scientific, clinical, administrative, and regulatory spheres.\n\nPhase B will involve a pilot clinical trial in patients with relapsed\u002Frefractory CD19-positive hematopoietic lymphoid neoplasms. The production of ARI-0001 cells consists of the genetic modification of autologous T cells through lentiviral transduction of a chimeric antigen receptor (CAR) targeting the CD19 surface antigen. The process is carried out in the CliniMACS Prodigy® closed transduction system, which for this study will be located at and operated by staff from the District Institute of Science, Biotechnology, and Innovation in Health (IDCBIS). This pilot clinical trial will use an open-label, single-arm, staggered enrollment design with a safety observation period. The patient will receive the cell product infusion following administration of a lymphodepletion regimen at the National Cancer Institute (NCI). The patient will remain hospitalized for 14 days after the CAR-T cell infusion ARI-001 for medical monitoring, with subsequent outpatient follow-up until 12 months post-infusion.\n\nSubsequently, the patient will be offered a new informed consent process to participate in outpatient follow-up for up to 15 years.",[400,28,29,401,402],"Adult B-cell Acute Lymphoblastic Leukemia","Diffuse Large B-Cell Lymphoma (DLBCL)","Chronic Lymphocytic Leukemia",[404,405,406,407,408,409,70,410,411],"Pilot","Implementation","Safety","ARI-0001","CAR-T","CD19","Leukemia","Colombia","2026-02-11",{"date":414,"type":38},"2026-02-17",{"date":327,"type":21},{"date":417,"type":21},"2029-09-01",{"name":419,"class":332},"GUSTAVO SALGUERO",{"id":421,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":422,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":423,"keywords":424,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":429,"leadSponsor":430,"locationsCount":46},"100519397",{"count":20,"type":21},[26,27,28,29,30,31],[33],"2026-01-26",{"date":427,"type":38},"2026-01-28",{"date":40,"type":38},{"date":42,"type":21},{"name":44,"class":45},{"id":432,"slug":433,"hasResults":11,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":437,"eligibilityCriteria":438,"healthyVolunteers":11,"sex":17,"minAge":439,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":56,"phases":442,"briefSummary":443,"conditions":444,"keywords":445,"overallStatus":301,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":450,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":4},"100620643","phase-2-efficacy-and-safety-of-tc011-in-relapsed-or-refractory-follicular-lymphoma-100620643","NCT07360288","Efficacy and Safety of TC011 in Relapsed or Refractory Follicular Lymphoma","A Multi-center, Single-arm, Open-label Phase II Study to Evaluate the Efficacy and Safety of TC011 in Patients With Relapsed or Refractory Follicular Lymphoma","TC011_FL_201","Inclusion Criteria:\n\n1. Ability to provide written informed consent.\n2. Age ≥19 years at the time of screening.\n3. Histologically confirmed follicular lymphoma Grade 1, 2, or 3a according to WHO 2017 classification.\n4. Relapsed or refractory disease after at least two prior systemic therapies including rituximab.\n5. ECOG performance status ≤2.\n6. Life expectancy ≥12 weeks.\n7. At least one measurable lesion (long diameter ≥1.5 cm).\n8. Adequate hepatic, renal, hematologic, pulmonary, and cardiac function.\n9. Eligible for leukapheresis and successful manufacture of TC011.\n10. Agreement to use effective contraception for at least 6 months after TC011 infusion.\n\nExclusion Criteria:\n\n1. Histologic transformation to diffuse large B-cell lymphoma or follicular lymphoma Grade 3b.\n2. Unresolved ≥Grade 2 toxicity from prior anticancer therapy (excluding hematologic abnormalities).\n3. Active or prior malignancy within 2 years, except adequately treated non-melanoma skin cancer or carcinoma in situ.\n4. Clinically significant cardiovascular disease within 6 months prior to screening.\n5. Active central nervous system involvement by lymphoma.\n6. Active uncontrolled infection, including HBV, HCV, HIV, or syphilis (protocol-defined exceptions apply).\n7. Active autoimmune or inflammatory neurologic disease.\n8. Rapidly progressive disease requiring urgent therapy.\n9. Prior treatment with anti-CD19 therapy, adoptive T-cell therapy, gene therapy, or allogeneic stem cell transplantation.\n10. Major surgery within 4 weeks prior to screening.\n11. Use of investigational agents within 4 weeks prior to screening.\n12. Known hypersensitivity to components of TC011.\n13. Pregnant or breastfeeding women.","19 Years",{"count":441,"type":21},40,[141],"This Phase II, multi-center, single-arm, open-label study evaluates the efficacy and safety of TC011, a CD19-targeted CAR-T cell therapy, in adult patients with relapsed or refractory follicular lymphoma (Grade 1, 2, or 3a).\n\nThe primary endpoint is objective response rate (ORR) assessed by independent review using the Lugano 2014 classification.",[28],[446,408,409,447,448],"Follicular Lymphoma","Adoptive Cell Therapy","Immunotherapy","2026-01-14",{"date":451,"type":38},"2026-01-22",{"date":453,"type":21},"2026-03-01",{"date":455,"type":21},"2030-02-28",{"name":457,"class":45},"TICAROS Co., Ltd.",{"id":459,"slug":460,"hasResults":11,"nctId":461,"briefTitle":462,"officialTitle":463,"acronym":4,"eligibilityCriteria":464,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":465,"targetDuration":4,"studyType":56,"phases":467,"briefSummary":468,"conditions":469,"keywords":4,"overallStatus":301,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":46},"100574331","phase-2-efficacy-and-safety-of-zuberitamab-combined-with-bendamustine-followed-by-monotherapy-maintenance-in-treatment-nave-follicular-lymphoma-100574331","NCT06757894","Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma","Efficacy and Safety of Zuberitamab and Bendamustine Combination Treatment Followed by Monotherapy Maintenance in Treatment-naïve Follicular Lymphoma: an Open-label, Prospective, Multicenter, Single-arm Phase II Clinical Study","Inclusion Criteria:\n\n1. Voluntary signing of informed consent.\n2. Age ≥ 18 years, no gender restriction.\n3. Histologically confirmed follicular lymphoma (grades 1-3a), CD20 positive by immunohistochemistry.\n4. No prior systemic treatment for FL.\n5. Ann Arbor stage III\u002FIV, or stage II with bulky disease (bulky disease defined as a tumor diameter ≥ 7 cm).\n6. Presence of measurable lesions.\n7. Meeting any of the following criteria:\n\n   1. B symptoms: unexplained fever \\>38°C, night sweats, unexplained weight loss \\>10% in the last 6 months.\n   2. Abnormal signs: splenomegaly, pleural effusion, ascites, etc.\n   3. Major organ damage: involvement of major organs leading to organ dysfunction.\n   4. Hematologic involvement: cytopenia \\[WBC \\\u003C 1.0 × 10⁹\u002FL and\u002For PLT \\\u003C 100 × 10⁹\u002FL\\]; leukemia-like manifestations (malignant cells \\> 5.0 × 10⁹\u002FL); elevated LDH levels; HGB \\\u003C 120 g\u002FL; β2-microglobulin ≥ 3 mg\u002FL.\n   5. Bulky disease: involvement of ≥ 3 tumors with each diameter ≥ 3 cm, or any lymph node or extranodal tumor with diameter ≥ 7 cm (for Ann Arbor stage III-IV patients).\n   6. Tumor enlargement of 20%-30% within 2-3 months, or approximately 50% enlargement within 6 months.\n8. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.\n9. Expected survival of \\> 6 months.\n\nExclusion Criteria:\n\n1. History of allergy to any component of monoclonal antibodies or investigational drugs.\n2. Central nervous system involvement.\n3. History of previous malignant tumors.\n4. Clinically significant cardiac or pulmonary diseases.\n5. Infection requiring intravenous antibiotic treatment or hospitalization within 4 weeks prior to enrollment; or infection requiring oral antibiotics within 2 weeks prior to enrollment; or symptoms related to an infection within 1 week prior to enrollment.\n6. Major surgery within 4 weeks prior to enrollment.\n7. Vaccination with live vaccines within 4 weeks prior to enrollment or planned live vaccination during the study.\n8. HIV antibody positive.\n9. Active syphilis infection, TP antibody positive, and anti-TP treatment within the last 2 years.\n10. Hepatitis C virus (HCV) antibody positive with HCV RNA quantitative test result exceeding the detection limit; Hepatitis B surface antigen (HBsAg) positive or Hepatitis B core antibody (HBcAb) positive, with Hepatitis B virus DNA quantitative test result exceeding the detection limit (for patients with HBsAg or HBcAb positive status, regardless of HBV-DNA detection, oral entecavir or other antiviral therapy must be initiated prior to enrollment and continued according to the physician's instructions during the trial).\n11. Pregnant or breastfeeding women, or planning to become pregnant during the study.\n12. Investigator determines the patient is unsuitable for enrollment or may not be able to complete the trial for other reasons.",{"count":466,"type":21},50,[141],"This is a prospective, single-arm, multicenter, phase ll clinical trial to evaluate the efficacy and safety of Zuberitamab and Bendamustine combination treatment in treatment-naïve follicular lymphoma patients.",[28],"2024-12-28",{"date":472,"type":38},"2025-01-03",{"date":474,"type":21},"2025-02-01",{"date":476,"type":21},"2034-02-01",{"name":331,"class":332},{"id":479,"slug":480,"hasResults":11,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":4,"eligibilityCriteria":484,"healthyVolunteers":11,"sex":17,"minAge":485,"maxAge":486,"enrollmentInfo":487,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":489,"conditions":490,"keywords":492,"overallStatus":301,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":46},"100572542","the-microbiome-in-blood-cancer-and-hlh-100572542","NCT06734624","The Microbiome in Blood Cancer and HLH","Using Blood and Stool Samples From Patients With Blood Cancer and\u002For Haemophagocytic Lymphohistiocytosis to Study the Influence of Host Microbial Factors on Toxicity and Survival","Inclusion Criteria:\n\n* Informed consent\n* Age 16-100 years\n* A blood cancer or clinically confirmed HLH by H-score criteria\n\nExclusion Criteria:\n\n* Known positive HIV, hepatitis B and\u002For hepatitis C serology (as laboratory not accredited to handle high-risk samples).\n* Active communicable disease eg SARS-CoV-2, monkeypox.","16 Years","100 Years",{"count":488,"type":21},750,"The bacteria and viruses in the bowel (gut microbiota; GM) have powerful effects on the immune system. GM changes are seen in patients with auto-immune diseases, where the immune system attacks normal tissues, and cancer, and for those with some forms of blood cancer, and appears to affect both responses to, and side-effects of treatment. The investigators want to examine the GM and the associated small molecules (metabolites) in adults with different forms of blood cancer, particularly those undergoing immunotherapy, those with have newly diagnosed follicular lymphoma, and also those with a severe hyperinflammatory disorder which causes problems similar to sepsis called Haemophagocytic lymphohistiocytosis (HLH), which is also often caused by an underlying lymphoma. The investigators want to collect blood and stool samples from patients and use the results of tests already performed in the NHS as well as recording how well patients responded to treatment. The samples will be used to identify novel targets within the GM and associated metabolites which contribute to side effects of, or response to immunotherapy, or are responsible for causing HLH which can be targeted to make treatment better tolerated. For patients with newly diagnosed indolent lymphoma the aim is to see if there are differences which may account for patients needing early or late treatment, or no treatment ever.",[62,28,491],"Haemophagocytic Lymphohistiocytosis",[493,351,117,494],"Microbiome","HLH","2024-12-12",{"date":497,"type":38},"2024-12-16",{"date":499,"type":21},"2025-01-01",{"date":501,"type":21},"2044-12",{"name":503,"class":332},"University of Nottingham",{"id":505,"slug":506,"hasResults":11,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":510,"eligibilityCriteria":511,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":512,"targetDuration":514,"studyType":23,"phases":4,"briefSummary":515,"conditions":516,"keywords":521,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":527,"lastUpdatePostDateStruct":528,"startDateStruct":530,"completionDateStruct":532,"leadSponsor":534,"locationsCount":536},"100352496","real-world-data-in-lymphoma-and-survival-in-adults-100352496","NCT03869619","REal World Data in LYmphoma and Survival in Adults","REAL WORLD DATA IN LYMPHOMA AND SURVIVAL IN ADULTS","REALYSA","Inclusion Criteria:\n\n* Signature of the consent form for participation in the REALYSA cohort\n* Aged over 18 at the time of inclusion\n* Diagnosed with lymphoma in the last 6 months (180 days)\n* Lymphoma subtype belonging to at least one of the 7 histological subtypes: diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, T-cell lymphoma, Hodgkin's lymphoma, Burkitt lymphoma\n\nExclusion Criteria:\n\n* Anti-lymphoma treatment already received (except pre-phase: typically corticosteroids, vincristine, cyclophosphamide, etoposide, alone or in combination)\n* Documented HIV infection\n* Any other lymphoma subtype not included in the list in Appendix 1. Of note, are excluded:\n\n  * Chronic lymphocytic leukemia\u002Fsmall lymphocytic lymphoma\n  * Hairy cell leukemia and variant\n  * Lymphoplasmacytic lymphoma\n  * Waldenström macroglobulinemia\n  * Primary DLBCL of the central nervous system (CNS)\n  * T-cell large granular lymphocytic leukemia\n  * Chronic lymphoproliferative disorder of NK cells\n  * Mycosis fungoides\n  * Sézary syndrome\n  * Primary cutaneous T cell lymphomas (mainly diagnosed and treated by dermatologists)\n  * Post-transplant lymphoproliferative disorders (PTLD)",{"count":513,"type":21},6000,"9 Years","REALYSA cohort is a population-based epidemiological platform in real-life for lymphomas designed to enrich prognostic data, by integrating together epidemiological, clinical and biological data.\n\nREALYSA is a platform perfectly set up to\n\n* Study prognostic factors using integrated epidemiological and biological data (genetics), to better characterize the determinants of refractoriness and relapse in patients with lymphoma, to follow the growing number of survivors and describe median to long-term sequela, second cancer, quality of life (QoL)…\n* Document treatment effectiveness in real life and observance\n* Address socio-economical questions",[517,28,29,30,518,519,520],"Diffuse Large B Lymphoma (DLBCL)","T-cell Lymphoma (T-NHL)","Hodgkin's Lymphoma (HL)","Burkitt Lymphoma (BL))",[522,523,524,525,526],"lymphoma","real life","cohort","epidemiology","PRO","2021-06-25",{"date":529,"type":38},"2021-06-28",{"date":531,"type":38},"2018-11-14",{"date":533,"type":21},"2027-11-14",{"name":535,"class":332},"Hospices Civils de Lyon",37]